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Abstract
Metal ion speciation in various biological systems has been extensively studied to elucidate its biological role and the
toxicity of the element of interest. In the present study, chromium speciation was performed by reacting Cr(III) nutritional
supplements [Cr(pic)3], where pic = 2-pyridinecarboxylato(), and a Cr(III) propionate complex, [Cr3O(OCOEt)6(OH2)3])+,
in calf serum. Cr(III) complexes in serum were fractionated using size-exclusion chromatography, and the Cr(III)
concentrations in each fraction were determined using graphite furnace atomic absorption spectroscopy. The results
showed that Cr(III) bound to both high- and low-molecular weight serum fractions. While Cr(III) was mainly bound to
albumin or transferrin, unknown low-molecular-weight serum fractions were also important in Cr binding. The Cr(III)
distribution in serum fractions was found to be time-dependent.

Abstrak
Biospesiasi dari Cr(III) yang Digunakan sebagai Suplemen Kesehatan pada Cairan Biologis. Studi mengenai
spesiasi ion logam dalam sistem biologi dilakukan untuk mengetahui peran biologis dan juga toksisitas dari suatu ion
logam. Pada penelitian ini telah dilakukan spesiasi ion Cr(III) yang digunakan sebagai suplemen kesehatan, yaitu
[Cr(pic)3], di mana pic = 2-piridinkarboksilato(), dan komplek dari Cr(III) propionat, [Cr3O(OCOEt)6(OH2)3])+, pada
serum. Komplek Cr(III) pada serum difraksionasi terlebih dahulu dengan metode kromatografi, kemudian konsentrasi
Cr(III) pada masing-masing fraksi ditentukan dengan metode AAS. Hasil yang didapatkan menunjukkan bahwa Cr(III)
terikat pada fraksi dengan berat molekul besar dan kecil. Fraksi serum dengan BM besar adalah albumin dan transferrin,
sedangkan fraksi dengan BM kecil tidak diketahui. Distribusi Cr(III) pada serum ditemukan bergantung pada waktu
inkubasi (time-dependent).
Keywords: AAS, chromium, size-exclusion chromatography, speciation

and humans [4]. Chromium deficiency is believed to lead
to signs and symptoms similar to those observed in type
2 diabetes and cardiovascular diseases, including elevated
blood glucose, serum cholesterol, and triglycerides levels as well as decreased insulin binding, impaired glucose tolerance, hypoglycaemia, and glycosuria [5,6].

Introduction
Chromium is probably the most controversial transition
element in terms of its nutritional activity and toxicity
[1]. While Cr(VI) was one of the first chemicals classified as a human carcinogen [2], Cr(III) has been widely
accepted as an essential nutrient that can play a role in
carbohydrate and lipid metabolism [3]. As such, many
of its complexes have been used as nutritional supplements for animals and humans as a means of enhancing
glucose metabolism, inducing weight loss, building muscle, and regulating blood glucose levels in type 2 diabetes for over four decades.

Tris(2-pyridinecarboxylate)chromium(III), also known as
Cr(III) picolinate [Cr(pic)3], where (pic = 2-pyridinecarboxylato(−)), has become the most popular Cr(III) nutritional supplement and the second largest-selling metal
supplement after calcium in the United States [7]. The
wide use of [Cr(pic)3] as a nutritional supplement is a
result of its high stability in biological media and high
bioavailability compared with other Cr(III) complexes [8].
It has been claimed that [Cr(pic)3] not only has positive

Further, Cr(III) is officially classified by the World Health
Organization as an essential trace element for animals
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effects as an anti-diabetic agent, but also has effects on
body tone, including increasing muscle mass and promoting weight reduction [5,9]. However, studies have
reported that [Cr(pic)3] has no beneficial effects on metabolism in healthy people, even when taken in combination with an exercise program [10,11].
Stearns et al. were the first to provide evidence for the
potential genotoxicity of [Cr(pic)3] in the ovary cells of
Chinese hamsters [12]. They also subsequently reported
mitochondrial damage [13] and mutagenic effects [14]
in these cells. The coordination of Cr(III) with picolinic
acid could be the factor that makes [Cr(pic)3] more
genotoxic than other Cr(III) complexes.
These findings raised concerns about the safety of using
[Cr(pic)3] as a nutritional supplement, particularly for longterm and high-dose use. Several complexes of Cr(III) with
other ligands, such as carboxylates ([Cr3O(O2CEt)6(OH2)3]+)
[15,16], amino acids ([Cr(L)3], L = histidine (his) or
phenylalanine (pa)) [17], niacin-bound chromium (NBC)
[18], and chromium-enriched yeast [19], have been investigated as alternative Cr(III) nutritional supplements.
The trinuclear Cr(III) oxo-carboxylato complex, Cr(III)
propionate complex ([Cr3O(O2CEt)6(OH2)3]+), was reported to have similar biological activities and a similar
molecular structure to those of chromodulin and was
thus proposed as a functional biomimetic of
chromodulin [20]. This complex has been patented by
Vincent and Davis for the treatment of disorders related
to chromium deficiency or as a nutritional supplement
[21].
The binding of metal ions to small biomolecules, such
as small peptides and amino acids in biological fluids, is
considered to have physiological importance [22]. However,
these species have not been well characterized, due to
isolation and purification problems. Thus, the identification
and characterization of low-molecular-weight (LMW)
protein-bound chromium, which could have implications
in the cellular mechanism of Cr action, are highly important. For these reasons, the current work investigates
Cr(III) complexes, focusing on Cr(III) nutritional
supplements used for their purported anti-diabetic activity.

Materials and Methods
Materials. All reagents of analytical or higher purity
grade were purchased from Merck or Sigma-Aldrich
and used as received: HCl (37% aqueous solution),
HNO3 (trace pure, 65% w/w in H2O), NaOH (99.9%),
NH4OAc, NaCl, Na2Cr2O7, acetonitrile (MeCN), picolinic
acid (pyridine-2-carboxylic acid, picH), ethanol, and
Cr(VI) standard solution (1000 ppm in 0.10 M HCl).
Water was purified using the Milli-Q technique.
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Commercial biochemicals from Sigma-Aldrich were
used as received: bovine serum albumin (BSA), bovine
apotransferrin, and myoglobin. Commercial calf serum
was purchased from Invitrogen. The SeeBlue Plus2
pre-stained standard (protein markers) and SDS-NuPAGE
Bis-Tris 4-12% electrophoresis systems were supplied
by Invitrogen (Cat. No 0323BOX). [Cr(pic)3]·H2O (A) and
[Cr3O(O2CEt)6(OH2)3](NO3)· 3H2O (B) were synthesized
according to the method recommended in existing
research [23].
Instrumentation. Size-exclusion chromatography (SEC)
was conducted in the AKTA Purifier 100/10 system at
room temperature using a SuperdexTM 200 10/200 GL
(GE Healthcare Bio-Sciences, Uppsala, Sweden), with
an optimum separation range between 10 and 600 kDa
(globular proteins) for the gel filtration column and a
bed dimension of 10  300-310 mm. Atomic absorption
spectroscopy was performed using a Varian SpectrAA20
spectrometer with a GTA 96 graphite tube atomizer to
determine the Cr(III) concentration in SEC fractions.
Sample Preparation. A stock solution of B in H2O
([Cr] = 100 mM) was prepared immediately before the
experiments. Due to the low solubility of A, its solutions
in an aqueous buffer or blood serum were prepared by
sonication (~10 min at 50 W and 298 K), and
undissolved solids were removed by centrifugation (~10
min at 10,000 rpm and room temperature). The total
concentration of Cr in the saturated solutions of A ([Cr]
= 0.30 to 1.0 mM] and B ([Cr] = 1.0 mM) in an aqueous
buffer or blood serum were determined by atomic
absorption spectroscopy. Figure 1 shows the molecular
structure of complexes A and B.
Separation of Serum Proteins Spiked with Cr(III)
Nutritional Supplements Using Size-Exclusion
Chromatography. The column buffer was prepared by
dissolving NH4OAc in Milli-Q water. It was filtered
through a 0.45-μm filter before use. SEC was performed
on an AKTA Purifier 100/10 system (Amersham
Biosciences) at room temperature with a Superdex 200
10/300 gel filtration column equilibrated in column
buffer (0.10 M NH4OAc, pH 7.2) at a flow rate of 0.50
mL min−1. Cr(III) compounds (saturated solutions of A
or B in blood serum, as prepared in section 2.3) were
incubated for 0, 1, 24, or 48 h at 37 C. The resulting
sample was dissolved in five volumes of column buffer
and filtered through a 0.20-μm filter before the mixture
was injected onto the column. An aliquot of the sample
(200 μL) was injected onto a Superdex 200 10/300 GL
column. The chromatographic separation was conducted
at a flow rate of 0.50 mL min−1, followed by UV
detection of bands at 260 nm. Isocratic elution with the
buffer was applied for 70 min. All operations were
carried out at room temperature. The same procedures
were applied to a sample of blood serum (unspiked, no
June 2017 Vol. 21  No. 2
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chromium compounds) diluted one in five in buffer
solution (0.10 M NH4OAc, pH 7.2).

Figure 1. Structures of Cr(III) Complexes used as Nutritional Supplements in this Study. Designations: A = [Cr(pic)3], B =
[Cr3O(O2CEt)6(OH2)3]+

Chromium Determination in SEC Fractions Using
Graphite Furnace Atomic Absorption Spectroscopy
(GFAAS). The sample solution was prepared by mixing
each SEC fraction (0.20 mL) with an aqueous HNO3
solution (65%, 0.20 mL) overnight at room temperature to
aid digestion of the protein. Aqueous HCl (0.10 M, 0.60
mL) was added to each sample prior to the analysis.
GFAAS was performed on a Varian SpectrAA20B
spectrometer with a GTA 96 graphite tube atomizer.
Three replicates for all samples were performed. A
standard solution of Na2Cr2O7 in 0.10 M HCl was used
for calibration (range of 0-25 ppb). Samples that had
concentrations out of the calibration range were diluted
10-50 fold until they were within range.
SDS-PAGE Analysis. The freeze-dried protein samples
and protein standards (BSA and bovine apo-transferrin)
were dissolved in a minimal amount of water; the final
concentration was ~1 mg mL−1, as determined by the
Bradford method. An aliquot of 4× NuPAGE LDS
sample buffer (containing 106 mM Tris HCl, 141 mM
Tris base, 2% LDS, 10% glycerol, 0.51 mM EDTA,
0.22 mM SERVA Blue G250, 0.175 mM Phenol red,
pH 8.5) was added to all gel samples. An aliquot of
sample (10 μL) was loaded per well onto a precast BisTris 4-12% SDS NuPAGE gel. Gels were run at 200 V
for 40 min using 20× NuPAGE MES SDS running
buffer (containing 50 mM MES, 50 mM Tris base, 0.1%
SDS, 1 mM EDTA, pH 7.3) in an XCellTM SureLock MiniCell apparatus (Invitrogen). Gels were then visualized with
an EZBlueTM gel staining reagent (Sigma) and destained
with water.

Results and Discussion
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Figures 2 and 3 show typical chromatograms of serum
spiked with A or B, under the specified conditions (0-48
h, 37 C) as well as the content of Cr(III) within the
serum fractions. The addition of A to the serum resulted
in an additional peak in the chromatogram for a species
that eluted at approximately 20 to 22 mL. This absorbance was likely due to the aromatic ligands in complex
A. With time, a slight shift was observed in the position
of this peak. Immediately after the addition of A to the
serum (0 h), Cr(III) accumulated, predominantly in fractions 19, 20, and 21. This corresponded to 19-21 mL of
the eluant, which were predicted to have low molecular
weights (LMW). The gradual binding of Cr(III) to highmolecular-weight (HMW) fractions, or fractions 12, 13,
and 14, was shown to occur during 1 to 24 h from the
beginning of the reaction (310 K). After 48 h of reaction, the amounts of Cr(III) bound to HMW and LMW
fractions of serum were roughly equal.
Similar results were observed when B was added to the
serum. However, a higher total amount of Cr(III) was
distributed in serum fractions than when the serum was
spiked with A. This may be due to A having a lower
Cr(III) concentration than B (Figure 3). No additional
peaks were observed after the addition of B to the blood
serum. At the beginning of B’s reaction with the serum
(0-1 h, 310 K), Cr(III) eluted primarily in LMW serum
fractions. After longer reaction times (24-48 h, 310 K),
Cr(III) accumulated mainly in HMW fractions (fractions
12-14).
Numerical data for Cr(III) binding to serum fractions
are given in Table 1. The total amount of Cr(III) recoveries were calculated from the Cr(III) concentration
dissolved in a saturated solution of A or B in serum. As
shown in Table 1, the total amount of recovered Cr(III)
June 2017 Vol. 21  No. 2
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never reached the amount of Cr(III) that was initially
introduced into the system, and the amount of unrecovered Cr(III) increased with increasing reaction times.

HMW fractions (8% and 5% for A and B, respectively)
immediately upon the addition of the compound (0 h,
310 K), even though Cr(III) bound mostly to LMW
fractions (68% and 89% for A and B, respectively).
During longer reaction times, as in the case of 24 h at
310 K, 36% and 43% of 44 total Cr(III) in A and B,
respectively, were bound to HMW fractions; 20% and
16% of total Cr(III) in A and B, respectively, were
bound to the LMW fractions. These findings are consistent with the slow kinetics of Cr(III) substitution.

Interestingly, it was observed that during the 48 h of
reaction times, Cr(III) was consistently found to bind to
both LMW and HMW fractions. An additional point to
be made is that the speciation within serum fractions
including Cr(III) was time dependent. For instance, a
small amount of Cr(III) was found to accumulate in
Elution profile of serum
spiked with A
Cr content
300

0h

800

*

400

10

15

20

25

30

35

1h

0

300
200

400

*

100

0

0

0

5

10

15

20

25

30

35

150

24 h

800

40

100

*

400

50

0

0

0

5

10

15

20

25

30

35

20

25

30

35

200
0

0
800

5

10

15

20

25

30

35

24 h

5

10

15

20

25

30

35

400

200

0

0

5

10

15

20

25

30

35

40
300

48 h

200

400

100
0

0

0

40

40
400

0

0

40
600

0

40

50

0

15

400

0

100

*

10

1h

150

400

5

400

800

48 h

800

800

Cr content (ppb)

800

40

Absorbance (mAu)

5

Cr content (ppb)

Absorbance (mAu)

0

0

0

1200
800
400
0

400

100
0

0h

800

200

Elution profile of serum
spiked with B
1600
Cr content

5

10

15

20

25

30

35

40

Eluted volume (mL)

Eluted volume (mL)

Figure 2. Comparison of Size-exclusion Chromatography
Profiles and Cr(III) Content in Serum Fractions
Spiked with A (0-48 h, 37 C) on a Superdex 200
Column. A Volume of 1 mL of Each Fraction was
Collected

Figure 3. Comparison of Size-exclusion Chromatography
Profiles and Cr(III) Content in Serum Fractions Spiked with A (0-48 h, 37 C) on a
Superdex 200 Column. A Volume of 1 mL of
Each Fraction was Collected

Table 1. Summary of GFAAS Analyses of Serum Fractions Spiked with A or B Under the Specified
Conditions (0-48 h, 310 K) Collected from SEC
Quantity of Cr(III) in Serum Fractions (%) a, b
Samples
A (0 h )
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HMW Fractions (fractions 12-14)

LMW Fractions
(fractions 19-21)

Total Cr(III)
Recovered (%)

8 ± 0.5

68 ± 1

84 ± 1.5

A (1 h)

31 ± 2

32 ± 1.1

75 ± 1

A (24 h)

36 ± 2.1

20 ± 1.9

66 ± 2

A (48 h)

22 ± 1.5

23 ± 1.5

57 ± 1.6

B (0 h)

5±2

89 ± 2.1

95 ± 1.5

B (1 h)

10 ± 2

51 ± 1.1

79 ± 1.3
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B (24 h)

43 ± 0.5

16 ± 0.6

71 ± 3.1

B (48 h)

36 ± 1.5

14 ± 1.1

62 ± 1.2

Figure 4. Chromatograms of Standard Proteins on a Superdex 200 Column (bed dimensions 10 × 300-310 mm). The Fractions
were Eluted with 0.10 M NH4OAc Buffer (pH 7.2, 298 K, Flow Rate of 0.50 mL min-1), with UV Detection at 260
nm. The Concentration of Each Protein was ~1 mg mL-1

exclusion Chromatographic Fractions of Serum
(unspiked): Fractions 9, 10, 11, 12, 13, and 14,
Respectively

Figure 5. SDS-PAGE Gel Electrophoresis of Serum Fractions in Comparison with Standard Proteins.
Lane 1 is a Pre-stained Protein Marker Mixture
from
Invitrogen:
Myosin
(188
kDa),
Phosphorylase (98 kDa), BSA (62 kDa), Glutamic Dehydrogenase (49 kDa), and Alcohol Dehydrogenase (38 kDa). Lane 2 is a BSA (bovine serum albumin) Standard. Lane 3 is a Bovine
APO-transferrin Standard. Lanes 4-9 are Size-
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Binding of Cr(III) to HMW and LMW protein fractions
has previously been reported [24,25]. These findings
suggest that the binding of Cr(III) to HMW proteins
LMW proteins was not as specific as previously assumed [26]. In addition, despite five decades of research, no functional Cr-containing enzymes or cofactors have been characterized conclusively, and some
hypotheses regarding their possible structure have been
refuted [27]. Cr(III)’s mode of action at a molecular
level is still an active area of debate. A recent study has
suggested that Cr(III) could act as a second messenger
or amplify insulin signaling, due to this ion’s ability to
bind to both HMW and LMW protein masses [28].
Preliminary assignments of the serum fraction natures
that bound Cr were performed by comparing the elution
times of standard proteins on the same column. Figure 4
shows that several peaks were observed for transferrin
June 2017 Vol. 21  No. 2
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and albumin standards. For these two proteins, the most
intense peak resulted from molecular weight calibration,
particularly the monomer; the weaker peaks most likely
resulted from dimers or other complexes [29]. The
HMW serum fractions that bound Cr could be either
albumin or transferrin, as the peaks of these proteins
were close together. However, separation using sizeexclusion chromatography for albumin and transferrin
generally resulted in poor resolution of their peaks [30].
In addition, the Cr(III)-binding LMW fractions are likely to correspond to standard peptides with molecular
weights around 1.3 to 1.5 kDa. However, since the position of the peak in size-exclusion chromatography is
dependent on the nature of the compounds, these results
only give a rough indication of molecular weight.
The identification of serum fractions that bound Cr was
carried out using protein gel electrophoresis via SDSPAGE, as presented in Figure 5. A difference in the spot
position of BSA (lane 2) with those of the protein
markers (lane 1) was observed in this gel. This is
because the mobility of protein markers can be affected
by the color labels attached to the markers or by
components of the sample buffer. The BSA spot of the
standard protein was used for molecular weight
calibration. Chromatographic fractions 9 to 12 (lanes 4
to 7) were detected as HMW proteins (molecular
weights of more than ~80 kDa). Small but distinct
differences were observed in the protein position of
fractions 13 and 14 (lanes 8 and 9). It is likely that
fractions 13 and 14 contained more albumin than
transferrin as the main spot position of these fractions
corresponds to the spot position of the albumin standard
(lane 2). Gel electrophoresis analysis could not be run
for the LMW serum fractions (fractions 19 to 21) due to
the low protein concentrations within these fractions
(less than ~1 mg mL1).

Conclusion
A combination of size-exclusion chromatographic and
atomic-absorption spectroscopic techniques have
demonstrated that Cr(III) compounds used as nutritional
supplements can bind to both HMW and LMW serum
fractions and that the distribution of Cr(III) within this
serum was time dependent. At the beginning of
reactions, Cr(III) was bound mostly to LMW serum
fractions; over ~24 h of reactions, it accumulated to a
larger extent in HMW serum fractions. The HMW
fractions associated with Cr(III) were albumin and
transferrin, the most abundant proteins in the serum. In
contrast, the identification of Cr(III)-containing LMW
substances has proven to be a demanding task. The
study of Cr biospeciation in biological fluids is
necessary to understand the biologically active forms of
Cr(III) nutritional supplements. Further research is still
required to elucidate the role and outcome of Cr that
binds to LMW fractions of serum. In summary, the
Makara J. Sci.

results of the current work support the hypothesis that
common reactive intermediates, including Cr(III)biomolecules, are likely responsible for both the antidiabetic activity of Cr(III) compounds and for the
genotoxicity and carcinogenicity of Cr(VI).
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